Our lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the DPX platform with a novel target: survivin.
Survivin, a cancer stem cell antigen and biomarker of cancer progression, is a particularly valuable target because it has the capacity to identify and disrupt cancer biology on multiple levels:
IMV has an exclusive, worldwide license to survivin from Merck KGaA.
DPX-Survivac in combination with metronomic cyclophosphamide hits the mark on several characteristics of an optimal immunotherapy approach. It has the capacity to:
Because we believe that DPX-Survivac has significant market potential across multiple indications, we have pursued a very deliberate, focused clinical strategy where we think it can add the most value. Building on preclinical research that indicated our anti-cancer therapies are able to induce T cell responses, we began pursuing therapies for DPX-Survivac where we believe it can most directly benefit underserved patients with hard-to-treat cancers, particularly those who have not responded to next-generation immuno-modulator therapies. Our primary initial indication for DPX-Survivac is in advanced ovarian cancer.